Albright GA. Cardiac arrest following regional anaesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51: 285–287.
Reiz S, Haggmark S, Johansson G, Nath S. Cardiotoxicity of ropivacaine – a new amide local anaesthetic agent. Acta Anaesthesiol Scand 1989; 33: 93–98.
Gaumann DM, Tassonyi E, Rivest RW, Fathi M, Reverdin AF. Cardiovascular and endocrine effects of clonidine premedication in neurosurgical patients. Can J Anesth 1991; 38: 837–843.
Carabine UA, Wright PMC, Moore J. Preanaesthetic medication with clonidine: a dose-response study. Br J Anaesth 1991; 67: 79–83.
De la Coussaye JE, Bassoul B, Brugada J, et al. Reversal of electrophysiologic and hemodynamic effects induced by high dose of bupivacaine by the combination of clonidine and dobutamine in anesthetized dogs. Anesth Analg 1992; 74: 703–711.
De Kock M, Le Polain B, Henin D, Vandewalle F, Scholtes JL. Clonidine pre-treatment reduces the systemic toxicity of intravenous bupivacaine in rats. Anesthesiology 1993; 79: 282–289.
Heath ML. Deaths after intravenous regional anaesthesia. Br Med J 1982; 285: 913–914.
Bruguerolle B, Attolini L, Lorec AM, Gantenbein M. Kinetics of bupivacaine after clonidine pretreatment in mice. Can J Anesth 1995; 42: 434–437.
Dabadie P, Bendriss P, Erny P, Mazat P. Uncoupling effects of local anaesthetics on rat liver mitochondria. FEBS Lett 1987; 226: 77–82.
Chazotte B, Vanderkooi G. Multiples sites of inhibition of mitochondria electron transport by local anaesthetics. Biochim Biophys Acta 1981; 636: 153–161.
Karniel M, Beitner N. Local anesthetic induce a decrease in the level of glucose 1,6-bisphospate, fructose 1,6-bisphospate, and ATP, and in the viability of melanoma cells. Mol Genet Metab 2000; 69: 40–45.
Sztark F, Tueux O, Erny P, Dabadie P, Mazat JP. Effect of bupivacaine on cellular oxygen consumption and adenine nucleotide metabolism. Anesth Analg 1994; 78: 335–339.
Eledjam JJ, de La Coussaye JE, Brugada J, et al. In vitro study on mechanisms of bupivacaine-induced depression of myocardial contractility. Anesth Analg 1989; 69: 732–735.
Sztark F, Malgat M, Dabadie P, Mazat JP. Comparison of the effects of bupivacaine and ropivacaine on heart cell mito-chondria bioenergetics. Anesthesiology 1998; 88: 1340–1349.
Scutari G, Marian M, Nindoli A, et al. Mitochondrial effects of L-ropivacaine, a new local anesthetic. Biochem Pharmacol 1998; 56: 1633–1637.
Takayanagi I, Onozuka S. Greater tension is developed at the same level of cytosolic Ca2+ concentration in the presence of clonidine, an adrenergic partial agonist, than in the presence of norepinephrine. J Pharmacobiodyn 1989; 12: 781–786.
Takayanagi I, Onozuka. Alpha 1-adrenergic partial agonists utilise cytosolic Ca2+ more effectively for contraction in aortic smooth muscle. Can J Physiol Pharmacol 1990; 68: 1329–1333.
Mio Y, Fukuda N, Kusakari Y, Tanifuji Y, Kurihara S. Bupivacaine attenuates contractility by decreasing sensitivity of myofilaments to Ca2+ in rat ventricular muscle. Anesthesiology 2002; 97: 1168–1177.
Brown CG, Jenkins J, Werman HA, Van Ligten P, Ashton J, Hamlin RL. The effect of UK14,304-18 (an alpha-2 adrenergic agonist) on myocardial blood flow during cardio-pulmonary resuscitation. Resuscitation 1989; 17: 243–250.
Sun S, Weil MH, Tang W, Kamohara T, Klouche K. Alpha-methylnorepinephrine, a selective alpha-2 adrenergic agonist for cardiac resuscitation. J Am Coll Cardiol 2001; 37: 951–956.
Kloucke K, Weil MH, Tang W, Povoas H, Kamohara T, Bisera J. A selective alpha-2 adrenergic agonist for cardiac resuscitation. J Lab Clin Med 2002; 140: 27–34.
Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. New Engl J Med 2001; 345: 588–594.